| Literature DB >> 34093478 |
Abdelmoneim K Abdalla1, Mutamed M Ayyash2, Amin N Olaimat3, Tareq M Osaili4,5, Anas A Al-Nabulsi5, Nagendra P Shah6, Richard Holley7.
Abstract
Exopolysaccharides (EPSs) are metabolites synthesized and excreted by a variety of microorganisms, including lactic acid bacteria (LAB). EPS serve several biological functions such as interactions between bacteria and their environments, protection against hostile conditions including dehydration, the alleviation of the action of toxic compounds (bile salts, hydrolyzing enzymes, lysozyme, gastric, and pancreatic enzymes, metal ions, antibiotics), and stresses (changing pH, osmolarity), and evasion of the immune response and phage attack. Bacterial EPSs are considered valuable by the food, pharmaceutical, and nutraceutical industries, owing to their health-promoting benefits and rheological impacts. Numerous studies have reported the unusual antimicrobial activities of various EPS against a wide variety of pathogenic microbes (bacteria, virus, and fungi). This review aims to provide a comprehensive examination of the in vitro and in vivo antimicrobial activities of different EPSs, mainly against foodborne bacterial, fungal, and viral pathogens. The mechanism of EPS action against these pathogens as well as the methods used to measure antimicrobial activities are critically reviewed.Entities:
Keywords: antibacterial; antifungal; antiviral; biopolymers; biopreservative
Year: 2021 PMID: 34093478 PMCID: PMC8170130 DOI: 10.3389/fmicb.2021.664395
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Antibacterial activity of LAB-derived EPS against Gram+ and Gram– bacterial pathogens.
| Genus | Specie/Strain | Monosaccharides | Mw (kDa) | Conc. mg/mL | Species targeted | Growth medium | Test Temp (°C) | Incubation time (h) | Da (mm) | MICb (mg/Ml) | Log RDc | References |
| Glu, Man, Gal, Rha, Fuc | 186.0 | 10 | BHI agar | 37 | 24 | 0.93 | – | – | ||||
| 10C | BHI agar | 37 | 24 | 1.49 | – | – | ||||||
| BHI agar | 37 | 24 | 7.43 | – | – | |||||||
| BHI agar | 37 | 24 | 9.14 | – | – | |||||||
| BHI agar | 37 | 24 | 3.16 | – | – | |||||||
| BHI agar | 37 | 24 | 5.86 | – | – | |||||||
| – | 36.0 | 0.064 –1 | MHB broth | 37 | 22–24 | – | 10 | – | ||||
| 0.064 –1 | MHB broth | 37 | 22–24 | – | 2 | – | ||||||
| – | – | 5 | LB agar | 37 | 48 | 9.3–13.6 | – | – | ||||
| – | – | 5 | LB agar | 37 | – | 9.5 | – | – | ||||
| – | – | 0.05-0.01 M | N agar/N broth | 28 | 48 | 9.53 | 0.0125 | |||||
| Ara, Man, Glu, Gal | 380.0 | 5 | BHI | 37 | 18 | – | – | 2.84 | ||||
| 5 | BHI | 37 | 18 | – | – | 3.61 | ||||||
| – | – | – | MHB broth | 30 | – | – | 6.25 | – | ||||
| Glu, Ara, Xyl | 7300.0 | 5 | N broth | 37 | 24 | – | – | 2.84 | ||||
| – | – | – | MHB broth | 30 | – | – | 9.3 | – | ||||
| Glu, Ara, Xyl | 7300.0 | 5 | N broth | 37 | 24 | – | – | 3.05 | ||||
| – | – | – | MHB broth | 37 | – | – | 8.5 | – | ||||
| Gluc and gal | – | 10S | BHI agar | 37 | 24 | 17.8 | 2 | – | ||||
| 10 | BHI agar | 37 | 24 | 10.2 | 6 | – | ||||||
| Glu, Man, Gal, Rha, Fuc | 186.0 | 10 | BHI agar | 37 | 24 | 1.49 | – | – | ||||
| 10C | BHI agar | 37 | 24 | 6.17 | – | – | ||||||
| 360.0 | 0.064 –1 | P. aeruginosa | MHB broth | 37 | 22–24 | – | 1 | – | ||||
| 360.0 | 0.064 –1 | MHB broth | 37 | 22–24 | – | 2 | – | |||||
| – | – | 5 | LB agar | 37 | 48 | 10.1–14.3 | – | – | ||||
| – | – | 5 | LB agar | 37 | 48 | 7.8–13.1 | – | – | ||||
| – | – | 5 | LB agar | 37 | 48 | 14 | – | – | ||||
| – | – | 5 | LB agar | 37 | 48 | 13.5 | – | – | ||||
| – | – | 5 | LB agar | 37 | – | 15 | – | – | ||||
| – | – | 5 | LB agar | 37 | – | 10.6 | – | – | ||||
| – | – | 0.05-0.01 M | N agar/N broth | 28 | 48 | 13.72 | 0.008 | – | ||||
| Ara, Man, Glu, Gal | 380.0 | 5 | BHI | 37 | 18 | – | – | 2.84 | ||||
| 380.0 | 5 | BHI | 37 | 18 | – | – | 2.98 | |||||
| Glu, Ara, Xyl | 7300.0 | 5 | N broth | 37 | 24 | – | – | 2.77 | ||||
| 5 | N broth | 37 | 24 | – | – | 2.84 | ||||||
| – | – | – | MHB broth | 37 | – | – | 17 | – | ||||
| MHB broth | 37 | – | – | 12.6 | – | |||||||
| MHB broth | 37 | – | – | 14.5 | – | |||||||
| MHB broth | 37 | – | – | 12.5 | – | |||||||
| MHB broth | 30 | – | – | 14.1 | – | |||||||
| Glu and gal | – | 10S | BHI agar | 37 | 24 | 12.1 | 4 | – | ||||
| BHI agar | 37 | 24 | 18.4 | <2 | – | |||||||
| BHI agar | 37 | 24 | 1.5 | – | – | |||||||
| Glu and gal | – | 10 | BHI agar | 37 | 24 | 5.1 | 10 | – | ||||
| BHI agar | 37 | 24 | 7.6 | 6 | – | |||||||
| BHI agar | 37 | 24 | 1.8 | – | – | |||||||
FIGURE 1Illustration of the potential EPS-cell wall interactions of Gram-negative (A) and Gram-positive (B) responsible for the antibacterial effects of EPSs.
Antifungal effects of the LAB-derived EPS.
| Producing organism | Monosaccharides | Purified/Crude/Modified | Conc. mg/mL | Pathogens | Mode of action | References | |
| Purified | 16 | Fungicidal effect | |||||
| Galactose-rich exopolysaccharides (EPS) | Purified | 0.050, 0.1, 0.2 | Play an essential role in decreasing hyphal formation and during adhesion to vaginal epithelial cells |
Antibiofilm activity of LAB-derived EPS against bacterial pathogens.
| Genus | Specie/Strain | Monosaccharides | Mw (kDa) | Conc. mg/mL | Target Pathogens | Growth medium | Test Temp (°C) | Inc. Time (h) | Inhibition (%) | References |
| Man, gluc, gal | – | 4 | TSB/BHI | 37 | 18 | 75.85 | ||||
| 4 | TSB/BHI | 37 | 18 | 65.56 | ||||||
| 4 | TSB/BHI | 37 | 18 | 61.45 | ||||||
| 4 | TSB/BHI | 37 | 18 | 55.5 | ||||||
| Xyl, Glu, Gal | 66.1 | 5 | LB broth | 37 | 24 | ∼ 43 | ||||
| Glu, man, gal, rha, fuc | 186.0 | 4 | LB broth | 37 | 24 | 56 | ||||
| 4 | LB broth | 37 | 24 | ∼ 27 | ||||||
| 4 | LB broth | 37 | 24 | 19.2 | ||||||
| Man, fru, gal, glu | 103.0 | 5 | LB broth | 37 | 24 | 45.13 | ||||
| Rha, glu, man | – | 5 | NB broth | 37 | 24 | 95.5 | ||||
| 5 | TSB broth | 37 | 12 | 30.2 | ||||||
| Man, glu, gal | – | 4 | TSB/BHI | 37 | 18 | 64.27 | ||||
| 4 | TSB/BHI | 37 | 18 | 63.84 | ||||||
| 4 | TSB/BHI | 37 | 18 | 62.89 | ||||||
| 4 | TSB/BHI | 37 | 18 | 61.45 | ||||||
| – | 36.0 | 0.256 | TSB-YE brot | 37 | 24 | – | ||||
| 0.256 | TSB-YE brot | 37 | 24 | – | ||||||
| – | – | 5 | LB broth | 37 | 24 | 70.5 | ||||
| 5 | LB broth | 37 | 24 | 61.1 | ||||||
| Rha, man, gal, glu | 8600.0 | 0.5 | Nutrient Broth | 37 | 24 | 80 | ||||
| Man, gluc, gal | – | 4 | TSB/BHI | 37 | 18 | 55.25 | ||||
| 4 | TSB/BHI | 37 | 18 | 55.12 | ||||||
| Xyl, Glu, Gal | 66.1 | 5 | LB broth | 37 | 24 | 47.02 | ||||
| 5 | LB broth | 37 | 24 | 25.8 | ||||||
| Glu, man, gal, rha, fuc | 186.0 | 4 | LB broth | 37 | 24 | ∼27 | ||||
| Man, fru, gal, glu | 103.0 | 5 | LB broth | 37 | 24 | 44.67 | ||||
| 5 | LB broth | 37 | 24 | 44.04 | ||||||
| 5 | LB broth | 37 | 24 | 12.7 | ||||||
| Rha, glu man | – | 5 | TSB broth | 37 | 24 | 12.1 | ||||
| 5 | TSB broth | 37 | 24 | 16.9 | ||||||
| Xyl, Glu, Gal | 66.1 | 5 | LB broth | 37 | 24 | ∼28 | ||||
| Man, glu gal | – | 4 | TSB/BHI | 37 | 18 | 59.42 | ||||
| Man, glu gal | – | 4 | TSB/BHI | 37 | 18 | 58.88 | ||||
| – | 36.0 | 0.256 | TSB-YE brot | 37 | 24 | – | ||||
| 0.256 | TSB-YE brot | 37 | 24 | – | ||||||
| – | – | 5 | LB broth | 37 | 24 | 28.4 | ||||
| 5 | LB broth | 37 | 24 | 63 | ||||||
| 5 | LB broth | 37 | 24 | 17.6 | ||||||
| 5 | LB broth | 37 | 24 | 51.1 | ||||||
| Rha, man, gal, glu | 8600.0 | 0.5 | TSB broth | 37 | 24 | 40 | ||||
Antiviral activities of LAB-derived EPS.
| Producing bacterium | Purified/Crude/Modified | Conc. mg/mL | Pathogens | Mode of action | References | |
| Purified | 0.02, 0.1, 0.5 | Adenovirus type 5 (HAdV-5) | Only EPS 26a from | |||
| Purified | 1.95 | Rotavirus | Interfering with the rotaviral attachment to cells | |||
| Purified | 1/2, 1/4, 1/8, 1/16 | Transmissible Gastroenteritis Virus (TGEV) | Inhibitory effect on TGEV | |||
| Purified neutral and acidic EPS | 0.1 | DsRNA similar to that found in many viruses | EPSs treatment induced the expression of IFN-α and IFN-β in PIE cells as well as the antiviral factors MxA and RNase L | |||
| Purified neutral and acidic EPS | 0.1 | Rotavirus | Enhanced expression of the antiviral factors interferon (IFN)-β, Myxovirus resistance gene A (MxA) and RNaseL | |||
| Purified | 1 | Rotavirus | Decreased the duration of diarrhea, restricted PIE lesions, reduced rotavirus replication in the intestine, and reduced the time to recovery |
FIGURE 2Schematic representation of different potential antiviral activities of LAB-derived EPSs including; (1) Prevention of the viral infection through direct binding of viral particles; (2) Obstruction via shielding or masking virus pattern recognition receptor (PRRs) sites; (3) and (4) Stimulation of the immune response in mucosal epithelial and dendritic cells (DC) through their PRRs, resulting in induction of various cytokine production which consequently could modulate antiviral effects by activation of CD+ T lymphocyte differentiation into cytotoxic T lymphocytes; induction of macrophages, stimulation of antiviral activity via phagocytes by activation of Th1, induction of B cell proliferation and viral neutralization activity via secretion of antibodies.